Taken together, these previous findings suggest that downregulating NOD2 is a potential therapeutic approach worth further research in clinical translation, and multilevel targeting of NOD2-mediated TIPE2 signaling pathways may provide a novel treatment for MIRI as well as other cardiovascular diseases [74–79]. The gene discussed is NOD2; the disease is cardiovascular disorder.